Innovent Biologics Inc., a leading biopharmaceutical company, has announced updated clinical data for IBI354, a novel anti-HER2 antibody-drug conjugate $(ADC)$, during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data, derived from a Phase 1/2 clinical study, highlights the promising anti-tumor efficacy and favorable safety profile of IBI354 across various advanced solid tumors, including ovarian and breast cancer. This study included 368 participants and demonstrated no dose-limiting toxicities at doses up to 18mg/kg, with the most common treatment-related adverse events being anemia, nausea, and a decrease in white blood cell count. The incidence of interstitial lung disease was low at 1.9% and limited to grades 1-2. These findings support Innovent's ongoing development of next-generation ADC therapies and further clinical studies are planned, including a Phase 3 study in platinum-resistant ovarian cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.